COAG.US Hemab Therapeutics Holdings, Inc. Common Stock
- Market cap
- USD 1.91B
- P/E
- -
- P/B
- 4.28x
- ROE
- -23.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is COAG.US undervalued?
Graham numberThe Graham number of Hemab Therapeutics Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hemab Therapeutics Holdings, Inc. Common Stock fundamental analysis
No fundamental analysis for Hemab Therapeutics Holdings, Inc. Common Stock yet.
Hemab Therapeutics Holdings, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor …
Full company profileHemab Therapeutics Holdings, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hemab Therapeutics Holdings, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -50.4M | -70.1M | -106M |
| EBITDA | -50.1M | -69.8M | -101M |
| Net Income | -48.7M | -63.9M | -98.9M |
| EPS | -1.10 | -2.33 | -2.12 |
| Balance Sheet | |||
| Total Assets | 96.3M | 195M | 443M |
| Total Liabilities | 212M | 371M | 13.4M |
| Shareholders' Equity | -115M | -177M | 429M |
| Cash & Short-term Investments | 74.4M | 185M | 430M |
| Total Debt | - | 1.22M | 965K |
| Cash Flow | |||
| Operating Cash Flow | -45.6M | -61.5M | -96.7M |
| Capital Expenditure | 282K | 16.0K | 344K |
| Free Cash Flow | -45.9M | -61.5M | -96.7M |
| Ratios | |||
| ROE | - | - | -23.0% |
| ROA | -50.6% | -32.8% | -22.3% |
| Debt to Equity | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hemab Therapeutics Holdings, Inc. Common Stock dividends
Hemab Therapeutics Holdings, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Hemab Therapeutics Holdings, Inc. Common Stock
- Insiders 11.00%
- Institutions 89.00%
- Public & others 0.00%
- Shares outstanding 46.7M
- Free float 20.3M
Top funds holding COAG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.51M | 7.51% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 556K | 1.19% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 552K | 1.18% | +2.69% | Oct 2026 |
| Fidelity Growth Company Fund | 524K | 1.12% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 502K | 1.07% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 439K | 0.94% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Growth A | 426K | 0.91% | -3.77% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 383K | 0.82% | -12.84% | Aug 2026 |
| Fidelity Blue Chip Growth | 236K | 0.51% | 0.00% | Sep 2026 |
| Fidelity Series Small Cap Opps | 215K | 0.46% | -19.64% | Aug 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 189K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 161K | 0.34% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 146K | 0.31% | 0.00% | Aug 2026 |
| T. Rowe Price New Horizons | 141K | 0.30% | -11.03% | Sep 2026 |
| JPMorgan Small Cap Blend A | 135K | 0.29% | -4.89% | Sep 2026 |
| Fidelity Series Growth Company | 124K | 0.27% | -3.34% | Aug 2026 |
| Vanguard Russell 2000 ETF | 115K | 0.25% | +1,517.61% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 115K | 0.25% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 112K | 0.24% | -0.38% | Oct 2026 |
| Fidelity Small Cap Growth | 96.3K | 0.21% | 0.00% | Aug 2026 |
Top institutions holding COAG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 7.81M | 16.72% | 0.00% | Jun 2026 |
| Novo A/S | 4.18M | 8.95% | 0.00% | Jun 2026 |
| FMR Inc | 3.70M | 7.92% | 0.00% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 3.60M | 7.72% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 3.60M | 7.71% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 2.09M | 4.47% | 0.00% | Jun 2026 |
| venBio Select Advisor LLC | 1.93M | 4.12% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 1.65M | 3.53% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.15M | 2.47% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 781K | 1.67% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 746K | 1.60% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 716K | 1.53% | 0.00% | Jun 2026 |
| Rock Springs Capital Management LP | 575K | 1.23% | 0.00% | Jun 2026 |
| Bellevue Group AG | 550K | 1.18% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 523K | 1.12% | 0.00% | Jun 2026 |
| BlackRock Inc | 284K | 0.61% | 0.00% | Jun 2026 |
| Deerfield Management Co | 275K | 0.59% | 0.00% | Jun 2026 |
| ExodusPoint Capital Management, LP | 218K | 0.47% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 212K | 0.45% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 160K | 0.34% | 0.00% | Jun 2026 |
Hemab Therapeutics Holdings, Inc. Common Stock company profile
- Company name
- Hemab Therapeutics Holdings, Inc. Common Stock
- Ticker
- COAG.US
- Exchange
- USA Stocks
- Listed since
- May 1, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
- Fiscal year end
- December
- Address
- 101 Main Street, Cambridge, MA, United States, 02142
- Phone
- (617) 553-3952
- Website
- hemab.com
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Hemab Therapeutics Holdings, Inc. Common Stock management
6- Dr. Benny Sorensen M.D., Ph.D.President, CEO & Director · born 1974
- Mr. Mads Nikolaj Behrndt-Eriksen M.Sc.CFO & GM · born 1983
- Dr. Catherine Eilleen Madigan M.D.Chief Medical Officer · born 1972
- Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D.Chief Operating Officer · born 1978
- Ms. Karen WeisbachChief People & Culture Officer
- Ms. Cecile Bonvoisin M.Sc.Senior Vice President of CMC & Manufacturing